Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis

医学 内科学 中止 放射治疗 不利影响 肿瘤科 乳腺癌 毒性 荟萃分析 癌症 转移性乳腺癌 胃肠病学
作者
Marcin Kubeczko,Michał Jarząb,Dorota Gabryś,Aleksandra Krzywon,Alexander Jorge Cortez,Amy J. Xu
出处
期刊:Radiotherapy and Oncology [Elsevier BV]
卷期号:187: 109839-109839 被引量:1
标识
DOI:10.1016/j.radonc.2023.109839
摘要

Background and PurposeThe addition of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) to endocrine therapy in hormone receptor-positive (HR+) human epidermal growth factor 2-negative (HER2-) breast cancer has led to practice-changing improvements in overall survival. However, there are conflicting data concerning the safety of CDK4/6i combination with radiotherapy, and no consensus guidelines exist to guide practice. We conducted a meta-analysis to assess the safety and feasibility of CDK4/6i treatment with radiotherapy.Materials and MethodsA comprehensive search was performed in PubMed/MEDLINE, Web of Science, and Scopus, for studies in advanced/metastatic breast cancer receiving CDK4/6i and radiotherapy with the provided safety data on the occurrence of toxicity. The main outcomes were safety (grade 3-5 adverse events), CDK 4/6i dose reduction, and the discontinuation rate due to toxicity.ResultsFifteen studies comprising 1133 patients with HR+/HER2- breast cancer patients were included. Among them, 617 pts received CDK4/6i and radiotherapy; the median follow-up was 17.0 months (IQR 9.2 – 18.0), and the median age was 58.8 years (IQR 55.5 - 62.5). The pooled prevalence of severe hematologic toxicity was 29.4% (95% CI 14.0% – 47.4%; I2 = 93%; τ2 = 0.084; p < 0.01 and severe non-hematologic toxicity was 2.8% (95% CI 1.1% – 4.8%; I2 = 0%; τ2 = 0.0; p = 0.67). The pooled prevalence of CDK4/6i dose reduction was 24.0% (95% CI 11.1% – 39.4%; I2 = 90%; τ2 = 0.052; p < 0.01) with no difference between CDK4/6i plus RT vs. CDK4/6i (odds ratio of 0.934; 95% CI 0.66 – 1.33; I2 = 0%; τ2 = 0.0; p = 0.56). The pooled prevalence of CDK4/6i discontinuation due to toxicity was 2.3% (95% CI 0.4% – 5.2%; I2 = 23%; τ2 = 0.002; p = 0.24).ConclusionThe findings of this study suggest that radiotherapy in addition to CDK4/6i treatment in breast cancer patients is generally safe and well tolerated and remains a viable treatment option.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小胡发布了新的文献求助10
刚刚
刚刚
完美世界应助合适的灵枫采纳,获得10
1秒前
昂莫达发布了新的文献求助10
1秒前
元宝团子完成签到,获得积分10
2秒前
ZZICU完成签到,获得积分10
3秒前
甜甜的静柏完成签到 ,获得积分10
3秒前
cyrong完成签到,获得积分10
3秒前
xzd1014完成签到,获得积分10
3秒前
Yangon完成签到,获得积分10
3秒前
陈杰完成签到,获得积分10
4秒前
小龅牙吖完成签到,获得积分10
4秒前
Potato完成签到,获得积分10
4秒前
5秒前
留胡子的丹彤完成签到 ,获得积分10
5秒前
5秒前
可靠从云完成签到 ,获得积分10
6秒前
6秒前
李健的小迷弟应助xzd1014采纳,获得10
6秒前
jou完成签到,获得积分10
7秒前
7秒前
李健应助炸药采纳,获得10
7秒前
麦克阿宇完成签到,获得积分10
7秒前
风中的双完成签到 ,获得积分10
7秒前
落寞的茉莉完成签到,获得积分20
7秒前
wqy完成签到 ,获得积分10
8秒前
好运连连完成签到,获得积分10
9秒前
zhengzhao应助爱撒娇的紫菜采纳,获得10
9秒前
卿莞尔完成签到 ,获得积分0
10秒前
书芹完成签到,获得积分10
10秒前
心灵美砖头完成签到,获得积分10
10秒前
szcyxzh完成签到,获得积分10
11秒前
领导范儿应助昂莫达采纳,获得10
11秒前
激昂的秀发完成签到,获得积分10
11秒前
豆腐kkkkk发布了新的文献求助10
12秒前
没头脑和不高兴完成签到,获得积分10
12秒前
12秒前
12秒前
顺利完成签到,获得积分10
14秒前
小蘑菇应助矮小的柠檬采纳,获得10
14秒前
高分求助中
Nickel, Cobalt and Palladium Catalysed Infarction with Ventricular following rich structural diversity 1000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968608
求助须知:如何正确求助?哪些是违规求助? 3513486
关于积分的说明 11168243
捐赠科研通 3248926
什么是DOI,文献DOI怎么找? 1794540
邀请新用户注册赠送积分活动 875188
科研通“疑难数据库(出版商)”最低求助积分说明 804676